Anyone interested in the other respirator indications may also want to read the posts below:
https://hotcopper.com.au/threads/msb-trading-2020-a-new-dawn.5553688/page-10398?post_id=49017245
https://hotcopper.com.au/threads/cell-therapy-news-articles.3765963/page-7738?post_id=49022824
I covered the other respiratory indications on Friday, but they must've got lost following all of the releases (and excitement) on Friday. I think you'll find we are evaluating COPD, asthma and emphysema (among other lung indications) as part of the COVID ARDs trial and we're also collaborating with the NHLBI with these studies. I expect if we show improvements to lung function in these patients then Novartis will want to pursue it further.
MSB Trading 2020 - a new dawn, page-10728
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
0.035(2.89%) |
Mkt cap ! $1.421B | |||
| Open | High | Low | Value | Volume |
| $1.21 | $1.25 | $1.18 | $4.096M | 3.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22000 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 36989 | 4 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |